论文部分内容阅读
bcl—2通过抑制细胞凋亡过程，从而导致肿瘤发生。为了检测bcl—2在乳腺癌中的表达情况及与临床病理的关系，应用枸椽酸—ABC——微波免疫组化技术．对87例福尔马林固定，石蜡包埋乳腺癌组织进行bcl—2癌基因蛋白表达的测定。结果显示：bcl—2蛋白在乳腺癌原发灶中的阳性表达率63．22％，其表达与ER、PR状况关系密切（均P＜0．001）；随着肿瘤病理学级别的升高，bcl—2蛋白表达率下降。bcl—2蛋白表达在区域淋巴结无转移组比淋巴结有转移组高（P＜0．001），bcl—2阳性表达率在术后生存期≥5年组比＜5年组高，且较少发生原位复发及脏器转移，差异具有显著性意义（P＜0．001）。提示；bcl—2蛋白参与乳腺癌的发生，并与好的预后因素相联系。
Bcl-2 inhibits apoptosis and leads to tumorigenesis. In order to detect the expression of bcl-2 in breast cancer and its relationship with clinical pathology, citrate-ABC-microwave immunohistochemical technique was used. 87 cases of formalin-fixed, paraffin-embedded breast cancer tissues were assayed for bcl-2 oncogene protein expression. The results showed that the positive expression rate of bcl-2 protein in primary breast cancer was 63.22%, and the expression of bcl-2 protein was closely related to ER and PR conditions (both P<0.001). With the increase of tumor pathological grade The bcl-2 protein expression rate decreased. The expression of bcl-2 protein was higher in lymph node metastasis group than in lymph node metastasis group (P<0.001). The positive expression rate of bcl-2 was higher in postoperative survival period ≥5 years group than in <5 year group, and less Occurred in situ recurrence and organ metastasis, the difference was significant (P <0.001). Tip; bcl-2 protein is involved in the occurrence of breast cancer, and is associated with good prognostic factors.